Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Randomized, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

NCT03659448 is registered in ClinicalTrials.gov with Surgimab as lead sponsor.

NCT NCT03659448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03659448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Randomized, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
Lead sponsor
Surgimab
Phase
Phase 3
Overall status
Recruiting
Start date
June 17, 2019
Completion date
December 31, 2024
Enrollment
300 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms